Is Aurobindo Pharma (AUROPHARMA) overvalued or fairly valued?

MarketChacha shows Aurobindo Pharma's valuation in context — a forward P/E of about 17.3, a price-to-book of about 2.4 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Aurobindo Pharma's revenue?

Aurobindo Pharma reported revenue of ₹33,653 Cr for FY2026, with net profit of ₹3,505 Cr, per official filings.

What is the share price of Aurobindo Pharma (AUROPHARMA)?

Aurobindo Pharma last traded at ₹1,555.90 (+1.5% on the day), as of 7/21/2026 — a delayed quote shown for education, not investment advice.

Aurobindo Pharma

AUROPHARMA · NSE · Pharma · India

₹1,555.90+1.5%

Delayed · as reported by Yahoo Finance · as of Jul 21, 2026, 5:38 AM

Snapshot

TickerAUROPHARMA

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

HeadquartersHyderabad, India

Market cap₹89,736 Cr

P/B2.4

Volume1.61L

Websitewww.aurobindo.com

Filings tracked0

About Aurobindo Pharma

Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Profile as reported by Yahoo Finance.

Who owns it

Promoters54.8%
Institutions29.3%
Public & other15.9%

189 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend7.8% → 10.4%

Margin has expanded by about 2.7 points — the business is getting more profitable.

Growth qualityrev 11% · PAT 22%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹9,398 Cr · EPS 17.56

Est. earnings growth +20.2%

Next fiscal year

Rev ₹43,414 Cr · EPS 89.97

Est. earnings growth +16.0%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹1,016.1052-wk range₹1,636.80

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Market cap

₹89,736 Cr

Day change

+1.5%

Fwd P/E

17.3

P/B

2.4

Div yield

0.26%

Beta

0.02

Revenue (FY2026)

₹33,653 Cr

Net margin

10.4%

Revenue CAGR (3y)

+10.6%

Profit CAGR (3y)

+22.1%

Net profit (FY2026)

₹3,505 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about AUROPHARMA

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹33,653 Cr	₹3,505 Cr	10.4%
FY2025	₹31,724 Cr	₹3,486 Cr	11.0%
FY2024	₹29,002 Cr	₹3,173 Cr	10.9%
FY2023	₹24,855 Cr	₹1,928 Cr	7.8%

Quarterly

Period	Revenue	Net profit	Net margin
2026Q1	₹8,853 Cr	₹921 Cr	10.4%
2025Q4	₹8,646 Cr	₹910 Cr	10.5%
2025Q3	₹8,286 Cr	₹848 Cr	10.2%
2025Q2	₹7,868 Cr	₹825 Cr	10.5%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.